Maxim Group Thinks TrovaGene’s Stock is Going to Recover


Maxim Group analyst Jason McCarthy maintained a Buy rating on TrovaGene (TROV) today and set a price target of $3. The company’s shares closed yesterday at $0.71, close to its 52-week low of $0.47.

McCarthy said:

“Trovagene announced that it has entered into an agreement with PoC Capital to fund clinical development of its lead asset, Onvansertib (polo-like kinase inhibitor 1, PLK1 inhibitor) in a Phase 1b/2 clinical trial in patients with metastatic colorectal cancer (mCRC).”

According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -7.4% and a 29.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

Currently, the analyst consensus on TrovaGene is a Moderate Buy with an average price target of $3, representing a 322.2% upside. In a report issued on January 15, Noble Financial also assigned a Buy rating to the stock.

See today’s analyst top recommended stocks >>

Based on TrovaGene’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $3.77 million. In comparison, last year the company had a GAAP net loss of $2.57 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts